Ironwood to Reduce Workforce Based on Phase III Trial Results
- Posted by ISPE Boston
- On October 1, 2020
Following confirmation that the Phase III trial of GERD drug IW-3718 failed to achieve the primary endpoint of achieving a statistically significant improvement in heartburn severity, Ironwood has announced plans to implement an organizational restructuring, reducing headcount by approximately 100 full-time employees, or nearly 35% of the current workforce. Following the changes, Ironwood expects to […]
Read More